Melanoma Clinical Trial
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
This was a retrospective real-world evidence cohort study.
Diagnosis of melanoma (The International Classification of Diseases, 9th Revision [ICD-9] 172.x & 10th revision [ICD-10] C43 or D03x).
Pathologic stage IV at initial diagnosis on or after 01 January 2011.
First-line treatment with IO monotherapy or combination therapy (nivolumab, pembrolizumab, ipilimumab + nivolumab) or TT combination therapy (dabrafenib + trametinib, vemurafenib+cobimetinib, encorafenib+binimetinib) on or after 01 January 2014.
Evidence of a BRAF test.
Evidence of a BRAF-positive result prior to or up to 30 days after first-line (1L) therapy initiation.
At least 18 years of age at the time of initiation of 1L treatment.
Documented receipt of a clinical trial treatment for cancer at any time on or after 01 January 2014.
Diagnosis of a second primary cancer or secondary cancer following initiation of 1L metastatic melanoma (MM) treatment.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
East Hanover New Jersey, 07936, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.